Delaware |
001-36537 |
83-0480694 |
||||||||||||
|
(State or other jurisdiction of
incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
||||||||||||
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
||||
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
||||
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
||||
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
||||
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||
| Common stock, $0.00001 par value per share | TRUP | The NASDAQ Stock Market LLC | ||||||
| (d) | Exhibits | |||||||
| Exhibit No. | Description | |||||||
| Press release regarding financial results issued by Trupanion, Inc. dated August 3, 2023 | ||||||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL) | |||||||
TRUPANION, INC. | |||||
By: |
/s/ Wei Li | ||||
Name: Wei Li |
|||||
Title: Interim Chief Financial Officer |
|||||


| Trupanion, Inc. Condensed Consolidated Statements of Operations (in thousands, except share data) | |||||||||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| (unaudited) | |||||||||||||||||||||||
| Revenue: | |||||||||||||||||||||||
| Subscription business | $ | 173,253 | $ | 145,808 | $ | 338,463 | $ | 285,647 | |||||||||||||||
| Other business | 97,313 | 73,603 | 188,432 | 139,763 | |||||||||||||||||||
| Total revenue | 270,566 | 219,411 | 526,895 | 425,410 | |||||||||||||||||||
| Cost of revenue: | |||||||||||||||||||||||
Subscription business(1) |
151,520 | 122,440 | 297,611 | 237,703 | |||||||||||||||||||
| Other business | 89,673 | 68,388 | 173,565 | 129,230 | |||||||||||||||||||
Total cost of revenue(2) |
241,193 | 190,828 | 471,176 | 366,933 | |||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
Technology and development(1) |
5,232 | 6,396 | 10,132 | 11,625 | |||||||||||||||||||
General and administrative(1) |
13,136 | 9,227 | 34,153 | 18,593 | |||||||||||||||||||
New pet acquisition expense(1) |
20,769 | 22,982 | 42,411 | 44,609 | |||||||||||||||||||
| Depreciation and amortization | 3,253 | 2,707 | 6,455 | 5,424 | |||||||||||||||||||
| Total operating expenses | 42,390 | 41,312 | 93,151 | 80,251 | |||||||||||||||||||
| Gain (loss) from investment in joint venture | (73) | (42) | (144) | (111) | |||||||||||||||||||
| Operating loss | (13,090) | (12,771) | (37,576) | (21,885) | |||||||||||||||||||
| Interest expense | 2,940 | 1,193 | 5,327 | 1,272 | |||||||||||||||||||
| Other income, net | (2,078) | (365) | (3,980) | (679) | |||||||||||||||||||
| Loss before income taxes | (13,952) | (13,599) | (38,923) | (22,478) | |||||||||||||||||||
| Income tax expense (benefit) | (238) | 19 | (429) | (5) | |||||||||||||||||||
| Net loss | $ | (13,714) | $ | (13,618) | $ | (38,494) | $ | (22,473) | |||||||||||||||
| Net loss per share: | |||||||||||||||||||||||
| Basic and diluted | $ | (0.33) | $ | (0.33) | $ | (0.93) | $ | (0.55) | |||||||||||||||
| Weighted average shares of common stock outstanding: | |||||||||||||||||||||||
| Basic and diluted | 41,383,411 | 40,738,738 | 41,246,411 | 40,660,797 | |||||||||||||||||||
(1)Includes stock-based compensation expense as follows: |
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| Cost of revenue | $ | 1,307 | $ | 1,830 | $ | 2,625 | $ | 3,666 | |||||||||||||||
| Technology and development | 627 | 1,101 | 1,335 | 2,009 | |||||||||||||||||||
| General and administrative | 2,948 | 3,066 | 11,167 | 5,489 | |||||||||||||||||||
| New pet acquisition expense | 1,755 | 2,637 | 3,841 | 5,019 | |||||||||||||||||||
| Total stock-based compensation expense | $ | 6,637 | $ | 8,634 | $ | 18,968 | $ | 16,183 | |||||||||||||||
(2)The breakout of cost of revenue between veterinary invoice expense and other cost of revenue is as follows: | |||||||||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| Veterinary invoice expense | $ | 206,738 | $ | 157,616 | $ | 400,875 | $ | 302,542 | |||||||||||||||
| Other cost of revenue | 34,455 | 33,212 | 70,301 | 64,391 | |||||||||||||||||||
| Total cost of revenue | $ | 241,193 | $ | 190,828 | $ | 471,176 | $ | 366,933 | |||||||||||||||
| Trupanion, Inc. Condensed Consolidated Balance Sheets (in thousands, except share data) | |||||||||||
| June 30, 2023 | December 31, 2022 | ||||||||||
| (unaudited) | |||||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 118,417 | $ | 65,605 | |||||||
| Short-term investments | 117,648 | 156,804 | |||||||||
| Accounts and other receivables, net of allowance for doubtful accounts of $701 at June 30, 2023 and $540 at December 31, 2022 | 265,648 | 232,439 | |||||||||
| Prepaid expenses and other assets | 18,882 | 14,248 | |||||||||
| Total current assets | 520,595 | 469,096 | |||||||||
| Restricted cash | 18,131 | 19,032 | |||||||||
| Long-term investments | 9,818 | 7,841 | |||||||||
| Property, equipment and internal-use software, net | 97,984 | 90,701 | |||||||||
| Intangible assets, net | 21,633 | 24,031 | |||||||||
| Other long-term assets | 18,153 | 18,943 | |||||||||
| Goodwill | 43,877 | 41,983 | |||||||||
| Total assets | $ | 730,191 | $ | 671,627 | |||||||
| Liabilities and stockholders’ equity | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 6,918 | $ | 9,471 | |||||||
| Accrued liabilities and other current liabilities | 29,893 | 32,616 | |||||||||
| Reserve for veterinary invoices | 56,202 | 43,734 | |||||||||
| Deferred revenue | 236,545 | 202,692 | |||||||||
| Long-term debt - current portion | 1,100 | 1,103 | |||||||||
| Total current liabilities | 330,658 | 289,616 | |||||||||
| Long-term debt | 102,934 | 68,354 | |||||||||
| Deferred tax liabilities | 2,940 | 3,392 | |||||||||
| Other liabilities | 4,901 | 4,968 | |||||||||
| Total liabilities | 441,433 | 366,330 | |||||||||
| Stockholders’ equity: | |||||||||||
| Common stock: $0.00001 par value per share, 100,000,000 shares authorized; 42,498,924 and 41,470,738 issued and outstanding at June 30, 2023; 42,041,344 and 41,013,158 shares issued and outstanding at December 31, 2022 | — | — | |||||||||
| Preferred stock: $0.00001 par value per share, 10,000,000 shares authorized; no shares issued and outstanding | — | — | |||||||||
| Additional paid-in capital | 519,450 | 499,694 | |||||||||
| Accumulated other comprehensive loss | (4,102) | (6,301) | |||||||||
| Accumulated deficit | (210,056) | (171,562) | |||||||||
| Treasury stock, at cost: 1,028,186 shares at June 30, 2023 and December 31, 2022 | (16,534) | (16,534) | |||||||||
| Total stockholders’ equity | 288,758 | 305,297 | |||||||||
| Total liabilities and stockholders’ equity | $ | 730,191 | $ | 671,627 | |||||||
| Trupanion, Inc. Condensed Consolidated Statements of Cash Flows (in thousands) | |||||||||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| (unaudited) | |||||||||||||||||||||||
| Operating activities | |||||||||||||||||||||||
| Net loss | $ | (13,714) | $ | (13,618) | $ | (38,494) | $ | (22,473) | |||||||||||||||
| Adjustments to reconcile net loss to cash provided by (used in) operating activities: | |||||||||||||||||||||||
| Depreciation and amortization | 3,253 | 2,707 | 6,455 | 5,424 | |||||||||||||||||||
| Stock-based compensation expense | 6,637 | 8,634 | 18,968 | 16,183 | |||||||||||||||||||
| Other, net | (188) | 5 | (585) | (74) | |||||||||||||||||||
| Changes in operating assets and liabilities: | |||||||||||||||||||||||
| Accounts and other receivables | (17,337) | (15,312) | (33,184) | (39,127) | |||||||||||||||||||
| Prepaid expenses and other assets | 552 | (761) | (3,213) | (2,821) | |||||||||||||||||||
| Accounts payable, accrued liabilities, and other liabilities | (1,316) | 2,509 | (6,464) | 703 | |||||||||||||||||||
| Reserve for veterinary invoices | 7,833 | (1,785) | 12,439 | (2,998) | |||||||||||||||||||
| Deferred revenue | 10,875 | 14,491 | 33,811 | 38,463 | |||||||||||||||||||
| Net cash provided by (used in) operating activities | (3,405) | (3,130) | (10,267) | (6,720) | |||||||||||||||||||
| Investing activities | |||||||||||||||||||||||
| Purchases of investment securities | (45,136) | (24,476) | (79,931) | (47,368) | |||||||||||||||||||
| Maturities and sales of investment securities | 43,859 | 19,013 | 117,652 | 31,212 | |||||||||||||||||||
| Purchases of property, equipment, and internal-use software | (4,735) | (3,926) | (9,919) | (7,479) | |||||||||||||||||||
| Other | 483 | (1,497) | 583 | (1,502) | |||||||||||||||||||
| Net cash provided by (used in) investing activities | (5,529) | (10,886) | 28,385 | (25,137) | |||||||||||||||||||
| Financing activities | |||||||||||||||||||||||
| Proceeds from debt financing, net of financing fees | — | (32) | 35,130 | 54,431 | |||||||||||||||||||
| Repayment of debt financing | (435) | (150) | (1,042) | (150) | |||||||||||||||||||
| Repurchases of common stock | — | (5,751) | — | (5,751) | |||||||||||||||||||
| Proceeds from exercise of stock options | 513 | 571 | 653 | 1,171 | |||||||||||||||||||
| Shares withheld to satisfy tax withholding | (171) | (632) | (1,024) | (2,930) | |||||||||||||||||||
| Net cash provided by (used in) financing activities | (93) | (5,994) | 33,717 | 46,771 | |||||||||||||||||||
| Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash, net | (184) | (835) | 76 | (696) | |||||||||||||||||||
| Net change in cash, cash equivalents, and restricted cash | (9,211) | (20,845) | 51,911 | 14,218 | |||||||||||||||||||
| Cash, cash equivalents, and restricted cash at beginning of period | 145,759 | 135,932 | 84,637 | 100,869 | |||||||||||||||||||
| Cash, cash equivalents, and restricted cash at end of period | $ | 136,548 | $ | 115,087 | $ | 136,548 | $ | 115,087 | |||||||||||||||
| The following tables set forth our key operating metrics: | |||||||||||||||||||||||||||||||||||||||||||||||
| Six Months Ended June 30, | |||||||||||||||||||||||||||||||||||||||||||||||
| 2023 | 2022 | ||||||||||||||||||||||||||||||||||||||||||||||
| Total Business: | |||||||||||||||||||||||||||||||||||||||||||||||
| Total pets enrolled (at period end) | 1,679,659 | 1,348,145 | |||||||||||||||||||||||||||||||||||||||||||||
| Subscription Business: | |||||||||||||||||||||||||||||||||||||||||||||||
| Total subscription pets enrolled (at period end) | 943,958 | 770,318 | |||||||||||||||||||||||||||||||||||||||||||||
| Monthly average revenue per pet | $ | 64.00 | $ | 64.24 | |||||||||||||||||||||||||||||||||||||||||||
| Lifetime value of a pet, including fixed expenses | $ | 470 | $ | 713 | |||||||||||||||||||||||||||||||||||||||||||
| Average pet acquisition cost (PAC) | $ | 241 | $ | 305 | |||||||||||||||||||||||||||||||||||||||||||
| Average monthly retention | 98.61 | % | 98.74 | % | |||||||||||||||||||||||||||||||||||||||||||
| Three Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||
| Jun. 30, 2023 | Mar. 31, 2023 | Dec. 31, 2022 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Dec. 31, 2021 | Sept. 30, 2021 | ||||||||||||||||||||||||||||||||||||||||
| Total Business: | |||||||||||||||||||||||||||||||||||||||||||||||
| Total pets enrolled (at period end) | 1,679,659 | 1,616,865 | 1,537,573 | 1,439,605 | 1,348,145 | 1,267,253 | 1,176,778 | 1,104,376 | |||||||||||||||||||||||||||||||||||||||
| Subscription Business: | |||||||||||||||||||||||||||||||||||||||||||||||
| Total subscription pets enrolled (at period end) | 943,958 | 906,369 | 869,862 | 808,077 | 770,318 | 736,691 | 704,333 | 676,463 | |||||||||||||||||||||||||||||||||||||||
| Monthly average revenue per pet | $ | 64.41 | $ | 63.58 | $ | 63.11 | $ | 63.80 | $ | 64.26 | $ | 64.21 | $ | 63.89 | $ | 63.60 | |||||||||||||||||||||||||||||||
| Lifetime value of a pet, including fixed expenses | $ | 470 | $ | 541 | $ | 641 | $ | 673 | $ | 713 | $ | 730 | $ | 717 | $ | 697 | |||||||||||||||||||||||||||||||
| Average pet acquisition cost (PAC) | $ | 236 | $ | 247 | $ | 283 | $ | 268 | $ | 309 | $ | 301 | $ | 306 | $ | 280 | |||||||||||||||||||||||||||||||
| Average monthly retention | 98.61 | % | 98.65 | % | 98.69 | % | 98.71 | % | 98.74 | % | 98.75 | % | 98.74 | % | 98.72 | % | |||||||||||||||||||||||||||||||
| The following table reflects the reconciliation of cash provided by operating activities to free cash flow (in thousands): | |||||||||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| Net cash used in operating activities | $ | (3,405) | $ | (3,130) | $ | (10,267) | $ | (6,720) | |||||||||||||||
| Purchases of property, equipment, and internal-use software | (4,735) | (3,926) | (9,919) | (7,479) | |||||||||||||||||||
| Free cash flow | $ | (8,140) | $ | (7,056) | $ | (20,186) | $ | (14,199) | |||||||||||||||
| The following tables reflect the reconciliation between GAAP and non-GAAP measures (in thousands except percentages): | ||||||||||||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||||||
| Veterinary invoice expense | $ | 206,738 | $ | 157,616 | $ | 400,875 | $ | 302,542 | ||||||||||||||||||
| Less: | ||||||||||||||||||||||||||
Stock-based compensation expense1 |
(856) | (1,022) | (1,695) | (2,195) | ||||||||||||||||||||||
| Other business cost of paying veterinary invoices | (72,443) | (50,378) | (137,592) | (94,714) | ||||||||||||||||||||||
| Subscription cost of paying veterinary invoices (non-GAAP) | $ | 133,439 | $ | 106,216 | $ | 261,588 | $ | 205,633 | ||||||||||||||||||
| % of subscription revenue | 77.0 | % | 72.8 | % | 77.3 | % | 72.0 | % | ||||||||||||||||||
| Other cost of revenue | $ | 34,455 | $ | 33,212 | $ | 70,301 | $ | 64,391 | ||||||||||||||||||
| Less: | ||||||||||||||||||||||||||
Stock-based compensation expense1 |
(428) | (754) | (876) | (1,385) | ||||||||||||||||||||||
| Other business variable expenses | (17,230) | (18,010) | (35,973) | (34,516) | ||||||||||||||||||||||
| Subscription variable expenses (non-GAAP) | $ | 16,797 | $ | 14,448 | $ | 33,452 | $ | 28,490 | ||||||||||||||||||
| % of subscription revenue | 9.7 | % | 9.9 | % | 9.9 | % | 10.0 | % | ||||||||||||||||||
| Technology and development expense | $ | 5,232 | $ | 6,396 | $ | 10,132 | $ | 11,625 | ||||||||||||||||||
| General and administrative expense | 13,136 | 9,227 | 34,153 | 18,593 | ||||||||||||||||||||||
| Less: | ||||||||||||||||||||||||||
Stock-based compensation expense1 |
(3,497) | (4,085) | (12,318) | (7,311) | ||||||||||||||||||||||
Non-recurring transaction or restructuring expenses2 |
(65) | — | (4,167) | — | ||||||||||||||||||||||
Development expenses3 |
(925) | (2,012) | (1,823) | (3,270) | ||||||||||||||||||||||
| Fixed expenses (non-GAAP) | $ | 13,881 | $ | 9,526 | $ | 25,977 | $ | 19,637 | ||||||||||||||||||
| % of total revenue | 5.1 | % | 4.3 | % | 4.9 | % | 4.6 | % | ||||||||||||||||||
| New pet acquisition expense | $ | 20,769 | $ | 22,982 | $ | 42,411 | $ | 44,609 | ||||||||||||||||||
| Less: | ||||||||||||||||||||||||||
Stock-based compensation expense1 |
(1,722) | (2,601) | (3,754) | (4,929) | ||||||||||||||||||||||
| Other business pet acquisition expense | (62) | (186) | (113) | (295) | ||||||||||||||||||||||
| Subscription acquisition cost (non-GAAP) | $ | 18,985 | $ | 20,195 | $ | 38,544 | $ | 39,385 | ||||||||||||||||||
| % of subscription revenue | 11.0 | % | 13.9 | % | 11.4 | % | 13.8 | % | ||||||||||||||||||
1Trupanion employees may elect to take restricted stock units in lieu of cash payment for their bonuses. We account for such expense as stock-based compensation according to GAAP, but we do not include it in any non-GAAP adjustments. Stock-based compensation associated with bonuses was approximately $0.1 million and $0.3 million for the three and six months ended June 30, 2023, respectively. | ||||||||||||||||||||||||||
2Consists of business acquisition transaction expenses, severance and legal costs due to certain executives' departures, and a $3.8 million non-recurring settlement of accounts receivable in the first quarter of 2023 related to uncollected premiums in connection with the transition of underwriting a third-party business to other insurers. | ||||||||||||||||||||||||||
3As we enter the next phase of our growth, we expect to invest in initiatives that are pre-revenue, including adding new products and international expansion. These development expenses are costs related to product exploration and development that are pre-revenue and historically have been insignificant. We view these activities as uses of our adjusted operating income separate from pet acquisition spend. | ||||||||||||||||||||||||||
| The following tables reflect the reconciliation of new pet acquisition expense, previously called "sales and marketing", to acquisition cost and net acquisition cost (in thousands): | |||||||||||||||||||||||||||||||||||||||||||||||
| Six Months Ended June 30, | |||||||||||||||||||||||||||||||||||||||||||||||
| 2023 | 2022 | ||||||||||||||||||||||||||||||||||||||||||||||
| New pet acquisition expense | $ | 42,411 | $ | 44,609 | |||||||||||||||||||||||||||||||||||||||||||
| Excluding: | |||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | (3,754) | (4,929) | |||||||||||||||||||||||||||||||||||||||||||||
| Acquisition cost | 38,657 | 39,680 | |||||||||||||||||||||||||||||||||||||||||||||
| Net of: | |||||||||||||||||||||||||||||||||||||||||||||||
| Sign-up fee revenue | (2,408) | (2,454) | |||||||||||||||||||||||||||||||||||||||||||||
| Other business segment pet acquisition expense | (113) | (295) | |||||||||||||||||||||||||||||||||||||||||||||
| Pet acquisition expense for commission-based policies | (1,815) | — | |||||||||||||||||||||||||||||||||||||||||||||
| Net acquisition cost | $ | 34,321 | $ | 36,931 | |||||||||||||||||||||||||||||||||||||||||||
| Three Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||
| Jun. 30, 2023 | Mar. 31, 2023 | Dec. 31, 2022 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Dec. 31, 2021 | Sept. 30, 2021 | ||||||||||||||||||||||||||||||||||||||||
| New pet acquisition expense | $ | 20,769 | $ | 21,642 | $ | 22,457 | $ | 22,434 | $ | 22,982 | $ | 21,627 | $ | 19,845 | $ | 19,708 | |||||||||||||||||||||||||||||||
| Excluding: | |||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | (1,722) | (2,032) | (2,079) | (2,108) | (2,601) | (2,328) | (2,136) | (2,112) | |||||||||||||||||||||||||||||||||||||||
| Acquisition cost | 19,047 | 19,610 | 20,378 | 20,326 | 20,381 | 19,299 | 17,709 | 17,596 | |||||||||||||||||||||||||||||||||||||||
| Net of: | |||||||||||||||||||||||||||||||||||||||||||||||
| Sign-up fee revenue | (1,189) | (1,219) | (1,191) | (1,339) | (1,252) | (1,202) | (1,162) | (1,268) | |||||||||||||||||||||||||||||||||||||||
| Other business segment pet acquisition expense | (62) | (51) | (65) | (181) | (186) | (109) | (76) | (134) | |||||||||||||||||||||||||||||||||||||||
| Pet acquisition expense for commission-based policies | (888) | (927) | (443) | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Net acquisition cost | $ | 16,908 | $ | 17,413 | $ | 18,679 | $ | 18,806 | $ | 18,943 | $ | 17,988 | $ | 16,471 | $ | 16,194 | |||||||||||||||||||||||||||||||
| The following tables reflect the reconciliation of adjusted EBITDA to net loss (in thousands): | |||||||||||||||||||||||||||||||||||||||||||||||
| Six Months Ended June 30, | |||||||||||||||||||||||||||||||||||||||||||||||
| 2023 | 2022 | ||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | $ | (38,494) | $ | (22,473) | |||||||||||||||||||||||||||||||||||||||||||
| Excluding: | |||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | 18,643 | 15,819 | |||||||||||||||||||||||||||||||||||||||||||||
| Depreciation and amortization expense | 6,455 | 5,424 | |||||||||||||||||||||||||||||||||||||||||||||
| Interest income | (3,780) | (394) | |||||||||||||||||||||||||||||||||||||||||||||
| Interest expense | 5,327 | 1,272 | |||||||||||||||||||||||||||||||||||||||||||||
| Other non-operating expenses | — | (1) | |||||||||||||||||||||||||||||||||||||||||||||
| Income tax benefit | (429) | (5) | |||||||||||||||||||||||||||||||||||||||||||||
| Non-recurring transaction or restructuring expenses | 4,167 | — | |||||||||||||||||||||||||||||||||||||||||||||
| (Gain) loss from equity method investment | — | (131) | |||||||||||||||||||||||||||||||||||||||||||||
| Adjusted EBITDA | $ | (8,111) | $ | (489) | |||||||||||||||||||||||||||||||||||||||||||
| Three Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||
| Jun. 30, 2023 | Mar. 31, 2023 | Dec. 31, 2022 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Dec. 31, 2021 | Sept. 30, 2021 | ||||||||||||||||||||||||||||||||||||||||
| Net loss | $ | (13,714) | $ | (24,780) | $ | (9,285) | $ | (12,914) | $ | (13,618) | $ | (8,855) | $ | (7,042) | $ | (6,819) | |||||||||||||||||||||||||||||||
| Excluding: | |||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | 6,503 | 12,140 | 8,412 | 8,306 | 8,462 | 7,358 | 6,808 | 6,443 | |||||||||||||||||||||||||||||||||||||||
| Depreciation and amortization expense | 3,253 | 3,202 | 2,897 | 2,600 | 2,707 | 2,717 | 2,770 | 2,944 | |||||||||||||||||||||||||||||||||||||||
| Interest income | (2,051) | (1,729) | (1,614) | (1,018) | (297) | (97) | (80) | (85) | |||||||||||||||||||||||||||||||||||||||
| Interest expense | 2,940 | 2,387 | 1,587 | 1,408 | 1,193 | 79 | 9 | — | |||||||||||||||||||||||||||||||||||||||
| Other non-operating expenses | — | — | — | — | (1) | — | — | (1) | |||||||||||||||||||||||||||||||||||||||
| Income tax expense (benefit) | (238) | (191) | (15) | 496 | 19 | (24) | 1,034 | (312) | |||||||||||||||||||||||||||||||||||||||
| Non-recurring transaction or restructuring expenses | 65 | 4,102 | 193 | 179 | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
| (Gain) loss from equity method investment | — | — | — | — | (131) | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Adjusted EBITDA | $ | (3,242) | $ | (4,869) | $ | 2,175 | $ | (943) | $ | (1,666) | $ | 1,178 | $ | 3,499 | $ | 2,170 | |||||||||||||||||||||||||||||||